Direct healthcare professional communications: A quantitative assessment study

Area of Science:

• Pharmacovigilance
• Drug Safety Communication
• Regulatory Compliance

Background:

• Direct healthcare professional communication (DHPC) letters are crucial for disseminating drug safety information.
• The Saudi Food and Drug Authority (SFDA) uses DHPC letters to inform healthcare professionals (HCPs) about potential drug risks.
• Evaluating compliance with international pharmacovigilance guidelines is essential for effective drug safety communication.

Purpose of the Study:

• To assess the compliance of DHPC letters issued by the SFDA with European Medicines Agency (EMA) pharmacovigilance guidelines.
• To identify areas of strength and weakness in SFDA's DHPC letter dissemination practices.

Main Methods:

• A retrospective observational study of all DHPC letters available on the SFDA website as of June 2020.
• Evaluation of 169 retrieved DHPC letters against EMA pharmacovigilance guideline requirements.
• Statistical analysis using SAS^® version 9.4.

Main Results:

• Most letters included the marketing authorization holder's logo (97%) and issuance date (98.8%).
• Common safety issues included hyperkalemia risk with RAAS medications (10.6%) and cardiac risks (9%).
• Areas for improvement included the omission of agreement statements with SFDA (10%) and missing MAH contact information (42 letters).

Conclusions:

• DHPC letters disseminated in Saudi Arabia demonstrate an acceptable level of compliance with international pharmacovigilance guidelines.
• While generally compliant, specific areas like agreement statements and contact information require attention for enhanced regulatory communication.